French researchers have found that British seniors over 75 who stop taking statins do not face higher mortality or major heart events. The study, published in The Lancet Healthy Longevity, suggests that for those using medication for primary prevention, discontinuation might be a safe option.
A 7.2% death rate in the discontinuation group
The study, which tracked 1 ,160 participants with an average age of 80, found that stopping statin therapy did not lead to worse survival outcomes compared to continuing the medication. According to the report published in The Lancet Healthy Longevity, the group that stopped their medication recorded a 7.2 percent death rate, which was actually slightly lower than the 7.9 percent observed in the group that continued treatment.
While the death rates were similar, other cardiovascular metrics showed slight variations. The researchers noted that major cardiovascular events, such as strokes and heart attacks, occurred in 5 percent of those who quit the medication versus 4.4 percent of those who stayed on it. The range of medications examined included common drugs such as simvastatin, atorvastatin, rosuvastatin, pravastatin, and fluvastatin. Because these differences were not statistically significant,the authors concluded that stopping the drugs was "noninferior" to continuing them.
The jump to 171 mg/dl LDL cholesterol
Despite the stable mortality rates, the physiological impact of stopping statins was immediate and measurable. The research highlighted a significant rise in low-density lipoprotein (LDL) levels among participants who discontinued their regimen. As reported by the study, average LDL levels climbed from 115 mg/dl to 171 mg/dl within just the first three months of stopping the medication.
In contrast,the group that continued their statin therapy maintained a stable average LDL level of 112 mg/dl. this massive spike in "bad" cholesterol presents a complex trade-off for medical professionals: while the immediate risk of death may not appear to rise in the short term, the underlying biochemical markers for heart disease change drastically once the medication is removed.
The 1.5 million UK seniors impacted by the findings
These findings carry significant weight for the United Kingdom, where nearly eight million people are currently on a statin regimen.. Specifically, approximately 1.5 million of those individuals are over the age of 75.. For decades, these medications have been considered "wonder drugs" capable of preventing roughly 80,000 heart attacks and strokes annually across Britain by lowering liver-produced choleesterol.
The debate over statin use often centers on the balance between preventing future events and managing the long-term pharmaceutical load. This study provides new data for the millions of British citizens who are currently prescribed these drugs, potentially offering a pathway for those who wish to reduce their medication in their later years.
Can these results apply to patients with existing heart disease?
Several critical questions remain regarding the applicability of this research to the general population. The study team acknowledged that their sample size of 1,160 participants was relatively small, which may limit the ability to generalize the findings. Furthermore, the researchers noted that the participants tended to have comparatively healthy lifestyles, which might not reflect the average 75-year-old patient.
Medical experts have also raised concerns about how this data should be applied in clinical practice. A cardiology professor from Sheffield warned that these results should not trigger a mass exodus from statin therapy, while the British Heart Foundation's chief scientific officer emphasized that statins remain life-saving for many. It remains unclear if these results would hold true for patients with secondary prevention needs—those who have already suffered a stroke or heart attack—or if the "noninferior" finding is strictly limited to primary prevention cases.
Comments 0